The new test uses the Vivalytic molecular diagnostics platform made by Bosch’s health-care division. The device is already used in hospitals, laboratories and medical practices to identify a range of bacterial and viral diseases including influenza and pneumonia. It will be available in Germany in April and sold in international markets, Bosch said.
“Infected patients can be identified and isolated faster,” Bosch Chief Executive Officer
The ability to detect Covid-19 is
While people still have to wait several days for results in many places, more companies are offering faster tests.
All of these offerings are so-called molecular diagnostic tests, which have confirmed the more than 470,000 cases known globally. They are the gold standard for diagnosing infections by looking for nucleic acids of the virus in people’s samples.
While highly accurate, they also require time, experienced technicians and materials -- including swabs -- that are in short supply. Governments have been trying to limit the people who get tested to those deemed most at risk for complications.
Bosch said its rapid test can be performed entirely at the point of care. It was developed in six weeks and can diagnose 10 respiratory pathogens simultaneously, with an accuracy rate of more than 95%, according to the manufacturer.
Scientists are simultaneously assessing the reliability of blood-based tests that could turbocharge countries’ ability to diagnose people. These kits, which look for antibodies against the virus behind the pandemic, are less reliable than the molecular tests but cheaper and easier to make and distribute.
(Adds other tests from Roche, Quest in fifth paragraph)
To contact the editors responsible for this story:
Anne Pollak, Frank Connelly
© 2020 Bloomberg L.P. All rights reserved. Used with permission.